ECCCLORE group program for people with addiction and trauma-related PTSD
Official title: Adaptation of the ECCCLORE Program for Patients With Addictive and Traumatic Problems: Feasibility and Acceptability
Run by Centre Hospitalier Universitaire de Nīmes · NCT07193914 · Data updated 2026-11-12
This program will try a group-based ECCCLORE therapy to see if it helps people who have addiction and PTSD or complex PTSD reduce substance use and impulsive or hostile behaviors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 1 site (Nîmes, Nîmes) |
| Status | Recruiting |
| Started | October 31, 2025 |
| Main results expected | March 2027 |
| Study ends | March 2027 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT07193914 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with one or more addictions who score at or above the ASSIST thresholds (≥11 for alcohol, ≥4 for other substances), have PTSD or cPTSD on the ITQ, can read and write French, provide informed consent, and are covered by a health insurance plan.
✕Probably not a fit
Patients with psychotic disorders, severe cognitive impairment (MoCA < 10), current manic or major depressive episodes, those unable to read/write French, or those unable to attend in-person group sessions are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional program adapts the ECCCLORE group therapy to treat adults with one or more substance addictions who also meet criteria for PTSD or complex PTSD on the ITQ. The intervention targets transdiagnostic processes such as impulsivity and hostile attribution bias that link trauma and addictive behaviors, delivered in a group format at CHU de Nîmes and requiring French language ability. Participants are screened with the ASSIST for substance use severity and excluded for psychotic disorders, severe cognitive impairment (MoCA < 10), current manic/hypomanic episodes, or major depressive episodes. The protocol is non-pharmacologic and focuses on psychotherapeutic techniques tailored to the trauma-addiction comorbidity.
Why it matters
Potential benefit: If successful, the program could help participants reduce substance use, improve emotion regulation, lower aggression and impulsivity, and improve overall quality of life.
How similar studies have gone: Integrated psychological treatments for trauma and addiction have shown some promise, but group-format interventions specifically targeting this comorbidity remain relatively novel and lack strong empirical support.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with one or more addictions * ASSIST questionnaire score greater than or equal to 11 for alcohol consumption and greater than or equal to 4 for other substances. * Diagnosis of PTSD and/or CPTSD assessed using the ITQ scale. * Ability to understand, write, and read French * The patient must have given their free and informed consent * The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: * The subject is participating in an interventional study involving a drug or medical device or a Category 1 study within 3 months prior to inclusion * The patient is under safeguard of justice or state guardianship * Patients with a psychotic disorder * Patients with severe cognitive impairment (MoCA \< 10) * Patients experiencing a manic or hypomanic episode * Patients experiencing a major depressive episode * Patients participating in an interventional study involving a drug or medical device or a Category 1 RIPH within 3 months prior to inclusion * Pregnant, parturient, or breastfeeding woman
Where it's running
-
CHU de Nîmes
Nîmes, Nîmes, France Recruiting
Study contacts
- Principal investigator: Laure Thebault — CHU de Nimes
- Study coordinator: Laure Thebault
- Email: laure.thebault@chu-nimes.fr
- Phone: 06.80.13.54.39
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Brain imaging to predict teens' response to cannabis treatment
This project will test whether teens' brain activity during a learning task can predict how well 14–17-year-olds do in a 10-week virtual reward program to reduce cannabis use.
-
Syringe-service telemedicine plus social-network HIV prevention program
This program will test whether training people who inject drugs to recruit and educate their peers through syringe service telemedicine and social networks increases HIV testing and use of prevention and treatment services in Maryland.
-
Web-based training program for providers treating PTSD and substance use disorders
This study is testing a new online training program for healthcare providers to help them better treat military Veterans who have both PTSD and substance use disorders.
-
Blended treatment for PTSD using computer-assisted therapy
This study is testing a new blended therapy for PTSD that combines online and in-person sessions to see if it works as well as the usual face-to-face treatment.
-
Vocal Signals of Craving in Addiction
Researchers will see if voice patterns can signal craving in adults with addictions by having them perform voice tasks and report their cravings in real time.
-
Hyperbaric Oxygen Therapy for Veterans With TBI and PCS
This study tests whether 40 HBOT sessions can change blood biomarkers in veterans with traumatic brain injury and persistent symptoms, and whether PTSD affects those biomarker changes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.